Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)

被引：0
|
作者：
Paul J. Hesketh
Gary Morrow
Anna W. Komorowski
Raza Ahmed
David Cox
机构：
[1] Lahey Clinic Medical Center,Department of Hematology Oncology
[2] University of Rochester School of Medicine and Dentistry,undefined
[3] Hematology-Oncology Associates of Rockland County,undefined
[4] Eisai,undefined
[5] Inc,undefined
[6] Eisai,undefined
[7] Inc,undefined
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; Serotonin antagonists; Nausea and vomiting; Low emetogenic chemotherapy; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2633 / 2637
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)
    Hesketh, Paul J.
    Morrow, Gary
    Komorowski, Anna W.
    Ahmed, Raza
    Cox, David
    SUPPORTIVE CARE IN CANCER, 2012, 20 (10) : 2633 - 2637
  • [2] A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy
    Takahashi, Tsutomu
    Okada, Takahiro
    Ikejiri, Fumiyoshi
    Ito, Shunsuke
    Okada, Yusuke
    Takahashi, Fumimasa
    Kumanomido, Satoshi
    Jo, Yumi
    Adachi, Koji
    Onishi, Chie
    Kawakami, Koshi
    Miyake, Takaaki
    Inoue, Masaya
    Suzuki, Ritsuro
    Suzumiya, Junji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 189 - 194
  • [3] Palonosetron for the prevention of chemotherapy-induced nausea and vomiting
    Mori-Vogt, Sherry
    Blazer, Marlo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (08) : 919 - 936
  • [4] Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer
    Navari, Rudolph M.
    FUTURE ONCOLOGY, 2010, 6 (07) : 1073 - 1084
  • [5] Palonosetron for the treatment of chemotherapy-induced nausea and vomiting
    Navari, Rudolph M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (17) : 2599 - 2608
  • [6] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10) : E1870 - E1879
  • [7] Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting
    Park, Sang Hee
    Binder, Gary
    Corman, Shelby
    Botteman, Marc
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 840 - 847
  • [8] A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy
    Tsutomu Takahashi
    Takahiro Okada
    Fumiyoshi Ikejiri
    Shunsuke Ito
    Yusuke Okada
    Fumimasa Takahashi
    Satoshi Kumanomido
    Yumi Jo
    Koji Adachi
    Chie Onishi
    Koshi Kawakami
    Takaaki Miyake
    Masaya Inoue
    Ritsuro Suzuki
    Junji Suzumiya
    International Journal of Clinical Oncology, 2018, 23 : 189 - 194
  • [9] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Boccia, Ralph
    Grunberg, Steven
    Franco-Gonzales, Edwin
    Rubenstein, Edward
    Voisin, Daniel
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1453 - 1460
  • [10] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Ralph Boccia
    Steven Grunberg
    Edwin Franco-Gonzales
    Edward Rubenstein
    Daniel Voisin
    Supportive Care in Cancer, 2013, 21 : 1453 - 1460
12345